Iovance Biotherapeutics Stock Price, News & Analysis (NASDAQ:IOVA)

$17.15 -0.80 (-4.46 %)
(As of 02/21/2018 12:49 PM ET)
Previous Close$17.15
Today's Range$16.95 - $18.10
52-Week Range$4.45 - $18.30
Volume866,600 shs
Average Volume1.21 million shs
Market Capitalization$1.53 billion
P/E Ratio-13.19
Dividend YieldN/A
Beta5.89

About Iovance Biotherapeutics (NASDAQ:IOVA)

Iovance Biotherapeutics logoIovance Biotherapeutics, Inc., formerly Lion Biotechnologies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. The Company's lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients' tumors, for the treatment of metastatic melanoma. As of December 31, 2016, it had an on-going Phase II clinical trial of its lead product candidate, LN-144, TIL for the treatment of metastatic melanoma. The Company is developing LN-145 to treat cervical and head and neck cancers. It is collaborating with the National Cancer Institute to evaluate unmodified TIL in other solid tumor indications, such as ocular melanoma, bladder, breast and lung cancer. It is collaborating with the NCI to evaluate TIL in combination with the checkpoint inhibitor, Keytruda.

Receive IOVA News and Ratings via Email

Sign-up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Diagnostics & Testing
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:IOVA
CUSIPN/A
Phone650-260-7120

Debt

Debt-to-Equity RatioN/A
Current Ratio20.11%
Quick Ratio20.11%

Price-To-Earnings

Trailing P/E Ratio-13.1922062137984
Forward P/E Ratio-12.70
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.68 per share
Price / Book6.40

Profitability

Trailing EPS($1.30)
Net Income$-52,890,000.00
Net MarginsN/A
Return on Equity-53.59%
Return on Assets-51.25%

Miscellaneous

Employees51
Outstanding Shares85,000,000

Iovance Biotherapeutics (NASDAQ:IOVA) Frequently Asked Questions

What is Iovance Biotherapeutics' stock symbol?

Iovance Biotherapeutics trades on the NASDAQ under the ticker symbol "IOVA."

How were Iovance Biotherapeutics' earnings last quarter?

Iovance Biotherapeutics Inc (NASDAQ:IOVA) announced its quarterly earnings data on Tuesday, October, 31st. The biotechnology company reported ($0.35) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.34) by $0.01. View Iovance Biotherapeutics' Earnings History.

Where is Iovance Biotherapeutics' stock going? Where will Iovance Biotherapeutics' stock price be in 2018?

10 brokers have issued 1 year target prices for Iovance Biotherapeutics' shares. Their predictions range from $13.00 to $31.00. On average, they expect Iovance Biotherapeutics' share price to reach $19.72 in the next twelve months. View Analyst Ratings for Iovance Biotherapeutics.

What are Wall Street analysts saying about Iovance Biotherapeutics stock?

Here are some recent quotes from research analysts about Iovance Biotherapeutics stock:

  • 1. According to Zacks Investment Research, "Iovance Biotherapeutics, Inc. is a biopharmaceutical company. It focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. Iovance Biotherapeutics Inc., formerly known as Lion Biotechnologies Inc., is based in SAN CARLOS, United States. " (1/20/2018)
  • 2. Cowen Inc analysts commented, "IOVA reported that the first patient in LN-145’s Phase II cervical cancer study has been." (8/16/2017)
  • 3. HC Wainwright analysts commented, "We project that one or more of these patients who achieved early PRs could transform to CRs with more follow up time as the infused TILs continue to act." (6/7/2017)

Who are some of Iovance Biotherapeutics' key competitors?

Who are Iovance Biotherapeutics' key executives?

Iovance Biotherapeutics' management team includes the folowing people:

  • Wayne Rothbaum, Interim Chairman of the Board
  • Maria Fardis Ph.D., President, Chief Executive Officer
  • Gregory T. Schiffman, Chief Financial Officer
  • James G. Bender Ph.D., Vice President
  • Iain D Dukes, Director
  • , Bio & Compensation - 
  • Ryan D. Maynard, Director
  • Sanford J. Hillsberg J.D., Independent Director
  • Merrill A. McPeak USAF, Independent Director
  • Jay Venkatesan M.D., Independent Director

Who owns Iovance Biotherapeutics stock?

Iovance Biotherapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Franklin Resources Inc. (5.86%), BlackRock Inc. (5.72%), Perceptive Advisors LLC (5.62%), Broadfin Capital LLC (2.75%), Victory Capital Management Inc. (2.47%) and Farallon Capital Management LLC (2.20%). View Institutional Ownership Trends for Iovance Biotherapeutics.

Who sold Iovance Biotherapeutics stock? Who is selling Iovance Biotherapeutics stock?

Iovance Biotherapeutics' stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Victory Capital Management Inc., Franklin Resources Inc., Broadfin Capital LLC, Wells Fargo & Company MN, Vident Investment Advisory LLC, Rhumbline Advisers and Allianz Asset Management GmbH. View Insider Buying and Selling for Iovance Biotherapeutics.

Who bought Iovance Biotherapeutics stock? Who is buying Iovance Biotherapeutics stock?

Iovance Biotherapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Prosight Management LP, QVT Financial LP, BlackRock Inc., Consonance Capital Management LP, Schwab Charles Investment Management Inc., TIAA CREF Investment Management LLC and Bank of New York Mellon Corp. View Insider Buying and Selling for Iovance Biotherapeutics.

How do I buy Iovance Biotherapeutics stock?

Shares of Iovance Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Iovance Biotherapeutics' stock price today?

One share of Iovance Biotherapeutics stock can currently be purchased for approximately $17.15.

How big of a company is Iovance Biotherapeutics?

Iovance Biotherapeutics has a market capitalization of $1.53 billion. The biotechnology company earns $-52,890,000.00 in net income (profit) each year or ($1.30) on an earnings per share basis. Iovance Biotherapeutics employs 51 workers across the globe.

How can I contact Iovance Biotherapeutics?

Iovance Biotherapeutics' mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The biotechnology company can be reached via phone at 650-260-7120 or via email at [email protected]


MarketBeat Community Rating for Iovance Biotherapeutics (IOVA)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  253 (Vote Outperform)
Underperform Votes:  109 (Vote Underperform)
Total Votes:  362
MarketBeat's community ratings are surveys of what our community members think about Iovance Biotherapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Iovance Biotherapeutics (NASDAQ:IOVA) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $19.72$15.31$15.31$14.86
Price Target Upside: 17.39% upside43.11% upside90.22% upside219.51% upside

Iovance Biotherapeutics (NASDAQ:IOVA) Consensus Price Target History

Price Target History for Iovance Biotherapeutics (NASDAQ:IOVA)

Iovance Biotherapeutics (NASDAQ:IOVA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/9/2018Jefferies GroupBoost Price TargetBuy$31.00LowView Rating Details
2/8/2018HC WainwrightSet Price TargetBuy$22.00HighView Rating Details
1/31/2018OppenheimerBoost Price TargetOutperform -> Outperform$13.00 -> $19.00LowView Rating Details
1/29/2018Wells Fargo & CoReiterated RatingBuy$23.00MediumView Rating Details
1/25/2018B. RileyReiterated RatingBuy$18.00MediumView Rating Details
1/22/2018Chardan CapitalReiterated RatingBuyHighView Rating Details
10/25/2017FBR & CoReiterated RatingBuy$17.50N/AView Rating Details
8/16/2017CowenReiterated RatingBuyMediumView Rating Details
5/10/2017Rodman & RenshawInitiated CoverageBuy -> Buy$13.00LowView Rating Details
3/8/2017Roth CapitalSet Price TargetBuy$14.00LowView Rating Details
6/6/2016SunTrust BanksDowngradeBuy -> Neutral$37.00 -> $30.50N/AView Rating Details
(Data available from 2/21/2016 forward)

Earnings

Iovance Biotherapeutics (NASDAQ:IOVA) Earnings History and Estimates Chart

Earnings by Quarter for Iovance Biotherapeutics (NASDAQ:IOVA)

Iovance Biotherapeutics (NASDAQ IOVA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/31/2017Q3 2017($0.34)($0.35)ViewN/AView Earnings Details
8/1/2017Q2 2017($0.35)($0.37)ViewN/AView Earnings Details
5/1/2017Q1 2017($0.28)($0.33)ViewListenView Earnings Details
3/7/2017Q4 2016($0.25)($0.25)ViewListenView Earnings Details
11/4/2016Q316($0.22)($0.32)ViewN/AView Earnings Details
8/8/2016Q2 2016($0.19)($0.23)ViewN/AView Earnings Details
5/9/2016Q1 2016($0.16)($0.14)ViewN/AView Earnings Details
3/10/2016Q4($0.20)($0.20)ViewN/AView Earnings Details
11/5/2015Q3 2015($0.20)($0.16)ViewN/AView Earnings Details
8/10/2015Q2 2015($0.17)($0.14)ViewN/AView Earnings Details
5/11/2015Q1 2015($0.11)($0.14)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Iovance Biotherapeutics (NASDAQ:IOVA) Earnings Estimates

2018 EPS Consensus Estimate: ($1.32)
2019 EPS Consensus Estimate: ($1.34)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($0.34)($0.29)($0.32)
Q2 20183($0.34)($0.30)($0.33)
Q3 20183($0.34)($0.32)($0.33)
Q4 20183($0.34)($0.33)($0.34)
Q1 20191($0.34)($0.34)($0.34)
Q2 20191($0.36)($0.36)($0.36)
Q3 20191($0.32)($0.32)($0.32)
Q4 20191($0.32)($0.32)($0.32)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Iovance Biotherapeutics (NASDAQ:IOVA)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Iovance Biotherapeutics (NASDAQ IOVA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 13.20%
Institutional Ownership Percentage: 65.08%
Insider Trades by Quarter for Iovance Biotherapeutics (NASDAQ:IOVA)
Insider Trades by Quarter for Iovance Biotherapeutics (NASDAQ:IOVA)

Iovance Biotherapeutics (NASDAQ IOVA) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/25/2016Sanford HillsbergDirectorSell54,000$8.95$483,300.00View SEC Filing  
8/22/2016Sanford HillsbergDirectorSell54,000$9.11$491,940.00View SEC Filing  
9/8/2015Sanford HillsbergDirectorSell32,500$6.99$227,175.00View SEC Filing  
5/6/2015Sanford HillsbergDirectorSell50,000$10.00$500,000.00View SEC Filing  
11/5/2013Manish SinghCEOBuy125,000$2.00$250,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Iovance Biotherapeutics (NASDAQ IOVA) News Headlines

Source:
DateHeadline
Iovance Biotherapeutics Inc (IOVA) Receives Average Rating of "Buy" from BrokeragesIovance Biotherapeutics Inc (IOVA) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - February 21 at 5:04 AM
Biotech Heats Up as Fear of Missing Out ReturnsBiotech Heats Up as Fear of Missing Out Returns
finance.yahoo.com - February 14 at 3:27 PM
Iovance Biotherapeutics to Present at the RBC Capital Markets 2018 Global Healthcare ConferenceIovance Biotherapeutics to Present at the RBC Capital Markets 2018 Global Healthcare Conference
finance.yahoo.com - February 14 at 3:27 PM
 Brokerages Anticipate Iovance Biotherapeutics Inc (IOVA) to Announce -$0.32 EPS Brokerages Anticipate Iovance Biotherapeutics Inc (IOVA) to Announce -$0.32 EPS
www.americanbankingnews.com - February 14 at 3:10 PM
Iovance Biotherapeutics (IOVA) Given New $31.00 Price Target at Jefferies GroupIovance Biotherapeutics (IOVA) Given New $31.00 Price Target at Jefferies Group
www.americanbankingnews.com - February 9 at 10:36 PM
Iovance Biotherapeutics (IOVA) Given a $22.00 Price Target by HC Wainwright AnalystsIovance Biotherapeutics (IOVA) Given a $22.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - February 8 at 11:14 PM
Iovance Biotherapeutics Inc (NASDAQ:IOVA) And The Healthcare Sector Outlook 2018Iovance Biotherapeutics Inc (NASDAQ:IOVA) And The Healthcare Sector Outlook 2018
finance.yahoo.com - February 4 at 3:28 PM
Iovance Biotherapeutics (IOVA) Upgraded at BidaskClubIovance Biotherapeutics (IOVA) Upgraded at BidaskClub
www.americanbankingnews.com - February 3 at 7:40 PM
Iovance Biotherapeutics Inc to Post FY2017 Earnings of ($1.38) Per Share, Oppenheimer Forecasts (IOVA)Iovance Biotherapeutics Inc to Post FY2017 Earnings of ($1.38) Per Share, Oppenheimer Forecasts (IOVA)
www.americanbankingnews.com - February 2 at 10:24 AM
Iovance Biotherapeutics (IOVA) in Focus: Stock Moves 5.1% Higher - NasdaqIovance Biotherapeutics (IOVA) in Focus: Stock Moves 5.1% Higher - Nasdaq
www.nasdaq.com - January 31 at 3:24 PM
Biotech Forum Daily Digest For January 31st - Iovance ... - Seeking AlphaBiotech Forum Daily Digest For January 31st - Iovance ... - Seeking Alpha
seekingalpha.com - January 31 at 3:24 PM
Iovance Biotherapeutics (IOVA) Price Target Raised to $19.00Iovance Biotherapeutics (IOVA) Price Target Raised to $19.00
www.americanbankingnews.com - January 31 at 2:50 PM
Iovance Biotherapeutics (IOVA) in Focus: Stock Moves 5.1% HigherIovance Biotherapeutics (IOVA) in Focus: Stock Moves 5.1% Higher
finance.yahoo.com - January 30 at 3:24 PM
Bloomberg Markets: Apple’s Chip Powerhouse, M&A OutlookBloomberg Markets: Apple’s Chip Powerhouse, M&A Outlook
www.bloomberg.com - January 30 at 6:31 AM
Wells Fargo & Co Reiterates Buy Rating for Iovance Biotherapeutics (IOVA)Wells Fargo & Co Reiterates Buy Rating for Iovance Biotherapeutics (IOVA)
www.americanbankingnews.com - January 29 at 7:00 PM
 Brokerages Anticipate Iovance Biotherapeutics Inc (IOVA) to Announce -$0.32 Earnings Per Share Brokerages Anticipate Iovance Biotherapeutics Inc (IOVA) to Announce -$0.32 Earnings Per Share
www.americanbankingnews.com - January 28 at 5:12 PM
Iovance Biotherapeutics (IOVA) PT Raised to $22.00Iovance Biotherapeutics (IOVA) PT Raised to $22.00
www.americanbankingnews.com - January 27 at 7:12 PM
Iovance Biotherapeutics Inc (IOVA) Receives Consensus Rating of "Buy" from BrokeragesIovance Biotherapeutics Inc (IOVA) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - January 27 at 5:34 AM
Why WW Grainger, Iovance Biotherapeutics, and Dolby Laboratories Jumped Today - Motley FoolWhy WW Grainger, Iovance Biotherapeutics, and Dolby Laboratories Jumped Today - Motley Fool
www.fool.com - January 26 at 3:25 PM
Iovance Biotherapeutics Announces Preliminary Phase 2 Data for TIL Treatment in Head and Neck and Cervical Cancers - GlobeNewswire (press release)Iovance Biotherapeutics Announces Preliminary Phase 2 Data for TIL Treatment in Head and Neck and Cervical Cancers - GlobeNewswire (press release)
globenewswire.com - January 26 at 3:25 PM
Iovance Biotherapeutics Inc to Post FY2022 Earnings of ($0.01) Per Share, Oppenheimer Forecasts (IOVA)Iovance Biotherapeutics Inc to Post FY2022 Earnings of ($0.01) Per Share, Oppenheimer Forecasts (IOVA)
www.americanbankingnews.com - January 26 at 3:16 PM
BRIEF-Iovance Biotherapeutics Announces Pricing Of Its Public Offering Of $150 Million Of Common StockBRIEF-Iovance Biotherapeutics Announces Pricing Of Its Public Offering Of $150 Million Of Common Stock
www.reuters.com - January 26 at 6:29 AM
Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $150 Million of Common Stock - NasdaqIovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $150 Million of Common Stock - Nasdaq
www.nasdaq.com - January 25 at 3:25 PM
Iovance Biotherapeutics (IOVA) Reports Preliminary Phase 2 Data for TIL Treatment in Head and Neck and Cervical ... - StreetInsider.comIovance Biotherapeutics (IOVA) Reports Preliminary Phase 2 Data for TIL Treatment in Head and Neck and Cervical ... - StreetInsider.com
www.streetinsider.com - January 25 at 3:25 PM
Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $150 Million of Common StockIovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $150 Million of Common Stock
finance.yahoo.com - January 25 at 3:25 PM
Here's Why Iovance Biotherapeutics Rose as Much as 29.1% TodayHere's Why Iovance Biotherapeutics Rose as Much as 29.1% Today
finance.yahoo.com - January 25 at 3:25 PM
Iovance Biotherapeutics (IOVA) Given "Buy" Rating at B. RileyIovance Biotherapeutics (IOVA) Given "Buy" Rating at B. Riley
www.americanbankingnews.com - January 25 at 1:58 PM
ANIK, GWPH Hit Record High, Menlo To Make Stock Market Debut, IOVA On WatchANIK, GWPH Hit Record High, Menlo To Make Stock Market Debut, IOVA On Watch
www.nasdaq.com - January 25 at 6:32 AM
Iovance Biotherapeutics Announces Preliminary Phase 2 Data for TIL Treatment in Head and Neck and Cervical CancersIovance Biotherapeutics Announces Preliminary Phase 2 Data for TIL Treatment in Head and Neck and Cervical Cancers
finance.yahoo.com - January 25 at 6:32 AM
Chardan Capital Initiates Coverage on Iovance Biotherapeutics (IOVA)Chardan Capital Initiates Coverage on Iovance Biotherapeutics (IOVA)
www.americanbankingnews.com - January 22 at 8:38 AM
Iovance adds to rally, up 12% - Seeking AlphaIovance adds to rally, up 12% - Seeking Alpha
seekingalpha.com - January 20 at 4:14 PM
Iovance Biotherapeutics (IOVA) Downgraded by Zacks Investment ResearchIovance Biotherapeutics (IOVA) Downgraded by Zacks Investment Research
www.americanbankingnews.com - January 20 at 12:33 PM
Iovance Biotherapeutics (IOVA) Upgraded to Buy by BidaskClubIovance Biotherapeutics (IOVA) Upgraded to Buy by BidaskClub
www.americanbankingnews.com - January 20 at 9:48 AM
Iovance Biotherapeutics (IOVA) Given a $16.00 Price Target by HC Wainwright AnalystsIovance Biotherapeutics (IOVA) Given a $16.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - January 17 at 8:32 AM
IOVANCE INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Iovance Biotherapeutics, Inc. - IOVAIOVANCE INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Iovance Biotherapeutics, Inc. - IOVA
finance.yahoo.com - January 13 at 9:00 AM
This Mornings Technical Outlook on Biotech Stocks -- Moleculin Biotech, Vanda Pharma, Iovance Biotherapeutics, and Bellicum PharmaThis Morning's Technical Outlook on Biotech Stocks -- Moleculin Biotech, Vanda Pharma, Iovance Biotherapeutics, and Bellicum Pharma
www.prnewswire.com - January 12 at 9:07 AM
Update in Lawsuit for Investors in Shares of Iovance Biotherapeutics, Inc (NASDAQ: IOVA), formerly Lion Biotechnologies, Inc. Announced by Shareholders FoundationUpdate in Lawsuit for Investors in Shares of Iovance Biotherapeutics, Inc (NASDAQ: IOVA), formerly Lion Biotechnologies, Inc. Announced by Shareholders Foundation
finance.yahoo.com - January 10 at 5:45 PM
IOVANCE INVESTIGATION INITIATED by Former...IOVANCE INVESTIGATION INITIATED by Former...
www.benzinga.com - January 6 at 9:02 AM
Iovance Biotherapeutics Inc (IOVA) Given Average Rating of "Buy" by AnalystsIovance Biotherapeutics Inc (IOVA) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - January 2 at 6:00 AM
BRIEF-Iovance Biotherapeutics Files For Mixed Shelf Of Up To $250 MlnBRIEF-Iovance Biotherapeutics Files For Mixed Shelf Of Up To $250 Mln
www.reuters.com - December 29 at 8:42 AM
Robbins Arroyo LLP: Iovance Biotherapeutics, Inc. (f/k/a Lion Biotechnologies, Inc.) (IOVA) Misled Shareholders According to a Recently Filed Shareholder Derivative ActionRobbins Arroyo LLP: Iovance Biotherapeutics, Inc. (f/k/a Lion Biotechnologies, Inc.) (IOVA) Misled Shareholders According to a Recently Filed Shareholder Derivative Action
finance.yahoo.com - December 28 at 5:13 PM
BidaskClub Downgrades Iovance Biotherapeutics (IOVA) to HoldBidaskClub Downgrades Iovance Biotherapeutics (IOVA) to Hold
www.americanbankingnews.com - December 22 at 7:32 PM
Iovance Biotherapeutics Inc (IOVA) Short Interest Up 31.3% in NovemberIovance Biotherapeutics Inc (IOVA) Short Interest Up 31.3% in November
www.americanbankingnews.com - December 16 at 4:14 AM
Iovance Biotherapeutics Inc (IOVA) to Post Q1 2019 Earnings of ($0.32) Per Share, Oppenheimer ForecastsIovance Biotherapeutics Inc (IOVA) to Post Q1 2019 Earnings of ($0.32) Per Share, Oppenheimer Forecasts
www.americanbankingnews.com - December 15 at 8:32 PM
Wired News – BioLife’s CryoStor(R) Freeze Media and HypoThermosol® Cell Storage Adopted by Iovance BiotherapeuticsWired News – BioLife’s CryoStor(R) Freeze Media and HypoThermosol® Cell Storage Adopted by Iovance Biotherapeutics
finance.yahoo.com - December 15 at 9:16 AM
Iovance Biotherapeutics (IOVA) PT Set at $13.00 by OppenheimerIovance Biotherapeutics (IOVA) PT Set at $13.00 by Oppenheimer
www.americanbankingnews.com - December 14 at 11:26 PM
Iovance Biotherapeutics (IOVA) Stock Rating Reaffirmed by B. RileyIovance Biotherapeutics (IOVA) Stock Rating Reaffirmed by B. Riley
www.americanbankingnews.com - December 14 at 2:42 PM
HC Wainwright Reaffirms Buy Rating for Iovance Biotherapeutics (IOVA)HC Wainwright Reaffirms Buy Rating for Iovance Biotherapeutics (IOVA)
www.americanbankingnews.com - December 14 at 9:02 AM
Contrasting Iovance Biotherapeutics (IOVA) and InVitae (NVTA)Contrasting Iovance Biotherapeutics (IOVA) and InVitae (NVTA)
www.americanbankingnews.com - December 14 at 5:30 AM
Iovance Biotherapeutics Announces Manufacturing Decision, Provides Clinical Updates and Highlights Pipeline Expansion at Analyst Day 2017Iovance Biotherapeutics Announces Manufacturing Decision, Provides Clinical Updates and Highlights Pipeline Expansion at Analyst Day 2017
www.nasdaq.com - December 13 at 5:59 PM

SEC Filings

Iovance Biotherapeutics (NASDAQ:IOVA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Iovance Biotherapeutics (NASDAQ:IOVA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Iovance Biotherapeutics (NASDAQ IOVA) Stock Chart for Wednesday, February, 21, 2018

Loading chart…

This page was last updated on 2/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.